Hyperlipidemia - Side-Effect of "Atypical" Neuroleptics?;Hyperlipidämie - Nebenwirkung von "atypischen" Neuroleptika?

Fortschritte der Neurologie Psychiatrie

Volumn 71, Issue 10, 2003, Pages 535-540

  Wetterling, Tilman ^a  

^a Vivantes Klinikum Hellersdorf   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CHOLESTEROL; CLOZAPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; TRIACYLGLYCEROL; ZOTEPINE;

CHOLESTEROL BLOOD LEVEL; DRUG SAFETY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; LIPOPROTEIN BLOOD LEVEL; PATHOPHYSIOLOGY; REVIEW; SCHIZOPHRENIA; TRIACYLGLYCEROL BLOOD LEVEL;

ANTIPSYCHOTIC AGENTS; HUMANS; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIAS; HYPERTRIGLYCERIDEMIA; LIPIDS;

EID: 0142229464     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-42871     Document Type: Review

References (60)

1. Naber D, Lambert M, Krausz M. Atypische Neuroleptika in der Behandlung schizophrener Patienten. 2. Aufl. Bremen: Uni-Med, 2000
2. Henderson DC. Clozapine: Diabetes mellitus, weight gain, and lipid abnormalities. J Clin Psychiatry 2001; 62 Suppl 23: 39-44
3. Kato MM, Goodnick PJ. Antipsychotic medication: Effects on regulation of glucose and lipids. Expert Opin Pharmacother 2001; 2: 1571-1582
4. McIntyre RS, McCann SM, Kennedy SH. Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities. Can J Psychiatry 2001; 46: 273-281
5. Assmann G, Schulte H. The importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) Study. Eur J Epidemiol 1992; 8 Suppl 1: 99-103
6. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 2000; 86: 943-949
7. Miller M. The epidemiology of triglyceride as a coronary artery disease risk factor. Clin Cardiol 1999; 22 (6 Suppl): II1-6
8. Laaser U. Nutzen und Kosten bei Früherkennung und Frühbehandlung der Hypercholesterinämie. Z Kardiol 1994; 83 Suppl 6: 163-167
9. Richter WO, Richter V, Rassoul F, Sonnichsen AC, Rotzsch W, Schwandt P. Kardiovaskuläre Risikofaktoren in den alten und neuen Bundesländern. Fortschr Med 1993; 111: 214-218
10. Spelsberg A, Weiland K, Stolpe S, Segerling M, Keil U. Bochumer Cholesterin und Blutdruckscreening-Studie 1990. Fortschr Med 1992; 110: 387-392
11. Hershcopf RJ, Elahi D, Andres R, Baldwin HL, Raizes GS, Schocken DD, Tobin JD. Longitudinal changes in serum cholesterol in man: an epidemiologic search for an etiology. J Chronic Dis 1982; 35: 101-114
12. McLaughlin T, Abbasi F, Lamendola C, Yeni-Komshian H, Reaven G. Carbohydrate-induced hypertriglyceridemia: an insight into the link between plasma Insulin and triglyceride concentrations. J Clin Endocrinol Metab 2000; 85: 3085-3088
13. Richter WO, Sonnichsen AC, Schwandt P. Results and efficacy of public screening for hypercholesterolemia: the Bavarian Cholesterol Screening Project. J Clin Epidemiol 1995; 48: 1307-1317
14. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356-359
15. Wetterling T. Hyperlipidämie - Nebenwirkung bei Behandlung mit einem atypischen Neuroleptikum (Zotepin)? Psychiat Prax 2002; 29: 438-440
16. Koro CE, Fedder DO, Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, Revicki D, Buchanan RW. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002; 59: 1021-1026
17. Clark ML, Johnson PC. Amenorrhea and elevated serum cholesterol produced by tri-fluoro-methylated phenothiazine. J Clin Endocrinol Metab 1960; 20: 641-646
18. Clark ML, Ray TS, Paredes A, Ragland RE, Costiloe JP, Smith CW, Wolf S. Chlorpromazine in women with chronic schizophrenia: the effect on cholesterol levels and cholesterol-behavior relationships. Psychosom Med 1967; 29: 634-642
19. Mefferd RB, Labrosse EH, Gawienowski AM. Influence of Chlorpromazine on biochemical variables of male schizophrenics. J Nerv Ment Dis 1958; 127: 167-179
20. Sasaki J, Funakoshi M, Arakawa K. Lipids and apolipoproteins in patients treated with major tranquillizers. Clin Pharmacol Ther 1985; 37: 684-687
21. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001; 58: 1172-1176
22. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Sys Pharm 1996; 53: 2079-2081
23. Spivak B, Roitman S, Vered Y, Mester R, Graff E, Talmon Y, Guy N, Gonen N, Weizman A. Diminished suicidal and aggressive behavior, high plasma norepinephrine levels, and serum triglyceride levels in chronic neuroleptic-resistant schizophrenic patients maintained on clozapine. Clin Neuropharmacol 1998; 21: 245-250
24. Gaulin BD, Markowitz JS, Caley CF, Nesbitt LA, Dufresne RL. Clozapine-associated elevation in triglycerides. Am J Psychiatry 1999; 156: 1270-1272
25. Wirshing DA. Adverse effects of atypical antipsychotics. J Clin Psychiatry 2001; 62 Suppl 21: 7-10
26. Braun GA, Paulois ME. Sterol metabolism: biochemical differences among butyrophenons. Int J Neuropsychiatry 1967; 3 Suppl: 26-27
27. Clark ML, Braun GA, Hewson JR, Serafetinides EA, Colmore JP, Rahhai DK. Trifluoperidol and cholesterol in man. Clin Pharmacol Ther 1968; 9: 333-340
28. Serafetinides EA, Colmore JP, Rahhai DK, Clark ML. Trifluoperidol in chronic male psychiatric patients. Behav Neuropsychiaty 1971; 3: 10-12
29. Simpson GM, Cooper TB. The effect of three butyrophenones on serum cholesterol levels. Curr Ther Res Clin Exp 1966; 8: 249-255
30. Simpson GM, Cooper TB, Braun GA. Further studies on the effect of butyrophenons on cholesterol synthesis in humans. Curr Ther Res Clin Exp 1967; 9: 413-418
31. Clark M, Dubowski K, Colmore J. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients. Clin Pharmacol Ther 1970; 11: 883-889
32. Sasaki J, Kumagae G, Sata T, Kuramitsu M, Arakawa K. Decreased concentration of high density lipoprotein cholesterol in schizophrenics treated with phenothiazines. Atherosclerosis 1984; 51: 163-169
33. Spivak B, Lamschtein C, Talmon Y, Guy N, Mester R, Feinberg I, Kotler M, Weizman A. The impact on serum lipids of clozapine treatment in chronic schizophrenic patients. Clin Neuropharmacol 1999; 2: 98-101
34. Meyer JM. A rectrospective comparison of weight, lipid, and glucose changes between olanzapine- and risperidone-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63: 425-433
35. Simpson G, Romano SJ, Horne RL et al. Ziprasidone versus olanzapine in schizophrenia: Result of a double-blind study. New Orleans: American Psychiatric Association Annual Meeting, NR 252, 2001: 68-69 (zitiert nach 3),
36. Dursun SM, Szemis A, Andrews H, Reveley MA. The effects of clozapine on levels of total cholesterol and related lipids in serum of patients with schizophrenia: a prospective study. J Psychiatry Neurosci 1999; 24: 453-455
37. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000; 157: 975-981
38. Leonard P, Halley A, Browne S. Prevalence of obesity, lipid and glucose abnormalities in outpatients prescribed clozapine. Ir Med J 2002; 95: 119-120
39. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21: 369-374
40. Melkersson KI, Hulting AL, Brismar KE. Elevated levels of Insulin, leptin, and blood lipids in olanzapine-treated patients with schizophrenia or related psychoses. J Clin Psychiatry 2000; 61: 742-749
41. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60: 767-770
42. Sheitman BB, Bird PM, Binz W, Akinli L, Sanchez C. Olanzapine-induced elevation of plasma triglyceride levels. Am J Psychiatry 1999; 156: 1471-1472
43. Kinon BJ, Basson BR, Gilmore JA, Tollefson GD. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001; 62: 92-100
44. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan MI. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20: 491-505
45. Keck Jr P, Buffenstein A, Ferguson J, Feighner J, Jaffe W, Harrigan EP, Morrissey MR. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial. Psychopharmacology 1998; 140: 173-184
46. Kingsbury SJ, Fayek M, Trufasiu D, Zada J, Simpson GM. The effects of Ziprasidone on cholesterol, triglycerides and glucose. J Clin Psychiatry 2001; 62: 347-349
47. Romano SJ, Cutler N, Weiden PJ, Simpson GM. Ziprasidone's effects on weight and lipids in patients with schizophrenia. Montreal: Poster, 23th Congress 23. - 27.6.2002
48. Wetterling T. Gewichtszunahme - eine unterschätzte Nebenwirkung atypischer Neuroleptika? Fortschr Neurol Psychiat 2000; 68: 546-556
49. Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E, Ernst ND, Horan M. Body mass index and the prevalence of hypertension and dyslipidemia. Obes Res 2000; 8: 605-619
50. Denke MA, Sempos CT, Grundy SM. Excess body weight. An under-recognized contributor to high blood cholesterol levels in white American men. Arch Intern Med 1993; 153: 1093-1103
51. Denke MA, Sempos CT, Grundy SM. Excess body weight. An under-recognized contributor to dyslipidemia in white American women. Arch Intern Med 1994; 154: 401-410
52. Thune I, Njolstad I, Lochen ML, Forde OH. Physical activity improves the metabolic risk profiles in men and women: the Tromsö Study. Arch Intern Med 1998; 158: 1633-1640
53. Ferreira MF, Sobrinho LG, Santos MA, Sousa MF, Uvnas-Moberg K. Rapid weight gain, at least in some women, is an expression of a neuroendocrine state characterized by reduced hypothalamic dopaminergic tone. Psychoneuroendocrinol 1998; 23: 1005-1013
54. Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin Endocrinol 1998; 48: 547-553
55. Bapista T, Lacruz A, Mendoza S de, Mendoza Guilleri JM, Silvera A, Angeles F, Mendoza MT, Hernandez L. Body weight gain after administration of antipsychotic drugs: correlation with leptin, insulin and reproductive hormones. Pharmacopsychiatry 2000; 33: 81-88
56. Brömel T, Blum WF, Ziegler A, Schulz E, Bender M, Fleischhaker C, Remschmidt H, Krieg J-C, Hebebrand J. Serum leptin levels increase rapidly after initiation of clozapine therapy. Mol Psychiatry 1998; 3: 76-80
57. Kraus T, Zimmermann U, Schuld A, Haack M, Hinze-Selch D, Pollmächer T. Zur Pathophysiologie der Gewichtsregulation im Rahmen der Therapie mit Psychopharmaka. Fortschr Neurol Psychiat 2001; 69: 116-137
58. Kametani T, Koshida H, Nagaoka T, Miyakoshi H. Hypertriglyceridemia is an independent risk factor for development of impaired fasting glucose and diabetes mellitus: a 9-year longitudinal study in Japanese. Intern Med 2002; 41: 516-521
59. McLaughlin T, Abbasi F, Lamendola C, Yeni-Komshian H, Reaven G. Carbohydrate-induced hypertriglyceridemia: an insight into the link between plasma insulin and triglyceride concentrations. J Clin Endocrinol Metab 2000; 85: 3085-3088
60. Wetterling T. Diabetes mellitus Typ II - induziert durch atypische Neuroleptika? Fortschr Neurol Psychiat 2003: 71